By: IPP Bureau
Last updated : May 11, 2022 10:35 am
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Ascletis Pharma announces the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functional cure of human immunodeficiency virus 1 (HIV-1) infected patients.
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection. Immune restoration/functional cure in HIV-1 infected patients is the second indication of ASC22 that obtained IND approval from U.S. FDA, in addition to the indication of functional cure of chronic hepatitis B (CHB) patients.
The U.S. FDA approved ASC22 trial is a multi-center, randomized, single-blind, placebo-controlled, Phase I/II clinical trial to evaluate the safety, efficacy, and pharmacokinetics characteristics of ASC22 in HIV infected patients on antiretroviral therapy (ART). The objectives of this Phase I/II trial are (1) to evaluate the safety of ASC22 versus placebo in participants on suppressive ART; (2) to determine whether ASC22 1.0 mg/kg, given once every four weeks, can improve HIV-1-specific cellular immune responses; and (3) to evaluate the effects of ASC22 versus placebo on latency reversal of HIV.
Ascletis announced that it had obtained a global and exclusive license as of November 8, 2021 from Suzhou Alphamab Co., Ltd. to develop and commercialize ASC22 for all viral diseases including Hepatitis B and HIV/AIDS. Ascletis books sales globally for ASC22 of all viral diseases.
"U.S. IND approval of ASC22 (Envafolimab) for HIV/AIDS treatment is a major step in our effort to pursue HIV functional cure. Meanwhile, we are looking forward to collaborating with the industrial leaders in the field of HIV/AIDS." said Jinzi J. Wu, PhD, Founder, Chairman and CEO of Ascletis.